Rapid Micro's Long-Awaited Margin Inflection Begins to Show
Q2 2026: Record consumables, rising validation, and a path to positive cash flow by 2028.
RPID · Earnings Call · 2026-08-07
A Small-Cap Rebuilding
Rapid Micro Biosystems (RPID) is a $93M micro-cap selling automated microbial quality-control systems. The stock has fallen 92% from its 2021 peak and dropped another 21% in the last 90 days – yet this quarter’s call suggests the operating story is finally turning. The company placed its 200th Growth Direct System, reported 11% revenue growth, and raised validation guidance to at least 27 systems for the year. For a business that has struggled to scale, the uptick in system utilization and Enterprise deployment discussions is a meaningful shift. As CEO Rob Spignesi put it, “We delivered a record 15% gross margin in the second quarter, reflecting strong execution against our margin expansion strategy.” — Robert Spignesi, President and Chief Executive Officer · 2026-08-07 That margin number – triple the prior year’s 4% – is the clearest signal yet that the company is moving beyond the “growth at all costs” phase.The Margin Story
Gross margin has historically been a pain point, often near zero or negative. The 15% print is a stepping stone to management's guide of mid-to-high 20% in Q4 and a long-term 50%+ exit rate by 2028. The inflection is driven by product costs, consumable efficiencies, and service leverage. CFO Sean Wirtjes told analysts on the call: “Recurring revenue increased 14% to $5 million compared to $4.4 million in Q2 2025.” — Sean Wirtjes, Chief Financial Officer · 2026-08-07 He added later, “the 2027 gross margin, we expect it to be higher than the exit rate for 2026.” — Sean Wirtjes, Chief Financial Officer · 2026-08-07 The confidence comes from locked-in vendor pricing (announced in March) and the partnership with MilliporeSigma to source materials. As Rob noted in May, when asked about the deal: “So basically, that agreement is linked to Growth Directs that MilliporeSigma sells that we will be the provider of all services associated...” — Robert Spignesi, President and Chief Executive Officer · 2026-05-13 Now, MilliporeSigma is starting to contribute placements, expanding the funnel into new geographies and adjacent markets. The company's gross margin has historically hovered near zero; the latest fundamentals reflect that legacy, but the current quarter's 15% and the guide to the mid-20s suggest a genuine step change in the cost structure.Tailwinds: Automation, CAR-T, and the MilliporeSigma Ramp
Customers are moving toward broader automation and data integration, and this is creating new sales opportunities. Rob highlighted a new trend among CDMOs and large manufacturers: “We're starting to see significant interest in more fully automated integrated systems.” — Robert Spignesi, President and Chief Executive Officer · 2026-08-07 The biomanufacturing capacity expansion and U.S. reshoring are expected to become meaningful contributors starting in 2027. The company also has strong penetration in CAR-T, where turnaround time matters: CAR T manufacturers rely on the Growth Direct for rapid results. This is a niche where the value proposition is undeniable. Meanwhile, the MilliporeSigma collaboration is ramping, and management is confident the second half will show a meaningful step-up in their contribution.The Path to Cash Flow
The company ended the quarter with $20M in cash, and a newly announced cost-efficiency program is expected to save $3M annually beginning in 2027. The path to positive cash flow by 2028 is supported by access to additional debt tranches and expected margin expansion. Sean summarized the adjusted EBITDA loss and the efficiency program on the call: “We expect these actions to reduce expenses and cash usage by around $1 million over the remainder of this year and approximately $3 million annually beginning in 2027.” — Sean Wirtjes, Chief Financial Officer · 2026-08-07 This is a marked shift from prior quarters when cash burn was the primary concern.The stock remains in a deep drawdown, and execution risk is high, but the margin inflection and the growing recurring revenue stream are real. For a micro-cap that has been written off, this quarter’s evidence suggests a plausible turnaround is underway.We believe the fundamentals of our business are stronger today than at any other point in our history.